Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q1 FY25 Earnings Presentation
34 slides from Supriya Lifescience's earnings presentation, Aug 10, 2024
Slide 1: Investor Presentation filing letter to BSE and NSE
Date: August 10, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Presen
Slide 2: Earnings Presentation Q1 FY25
Earnings Presentation Q1 FY25
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Table of Contents
TABLE OF CONTENTS Sustainability 1. Q1 FY25 Highlights Growth 2. Company Overview 3. Historical Financial Performance Profitability 4. Future Outlook
Slide 5: Q1 FY25 Highlights
Q1 FY25 Highlights
Slide 6: Q1 FY25 Highlights: Regional Performance
Q1 FY25 Highlights (in INR mn) Revenue EBITDA PBT PAT Quarterly Rs. 1,606.3 mn Rs. 625.4 mn Rs. 597.7 mn Rs. 446.4 mn 21.7 % YoY 40.6 % YoY 40.2 % YoY 56.6 % YoY Business Mix Revenue Contribution – By Region Regional Performance 51% 41% 43% Q1FY24 35% 33% 34% Q4FY24 Q1FY25 10% 11% 9% 9% 6% 3% 6% 5%
Slide 7: Q1 FY25 Highlights
Q1 FY25 Highlights (in INR mn) Revenue EBITDA PBT PAT +22% +41% +40% +57% 1,581.8 1,606.3 +2% 625.4 597.7 446.4 1,320.2 555.0 +13% 531.8 +12% 364.0 +23% 444.9 426.4 285.1 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 Q1FY24 Q4FY24 Q1FY25 EBITDA Margins PAT Margins +524 bps +620 bps
Slide 8: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Therapeutic Areas 48.5% Q1FY24 45.9% Q1FY25 19.5% 11.6% 11.5% 11.1% 5.8% 7.0% 5.0% 4.6% 4.0% 1.3% Analgesic/Anesthetic Anti-histamine Vitamins Anti-Asthmatic Anti-allergic Anti-hypertensive 7 Q1 FY25 Earnings Presentation
Slide 9: Q1 FY25 Profit & Loss Statement
Q1 FY25 Profit & Loss Statement Particulars (in INR mn) Q1 FY25 Q1 FY24 Y-o-Y Q4 FY24 Q-o-Q FY24 Revenue from Operations 1,606.3 1,320.2 21.7% 1,581.8 1.5% 5,703.7 Cost of Materials Consumed 557.3 475.3 483.6 1,914.3 Changes in Inventories of Finished Goods and Work in Progress -71.29 -3.1 99.1 303.
Slide 10: Company Overview
Company Overview
Slide 11: Business Overview
Business Overview Approved facility with Diversified operations Largest exporter of strong IP Niche product basket of with presence in Chlorpeniramine Maleate, Ketamine 32 APIs 128 Hydrochloride and Salbutamol Sulphate from India 18 DMFs with USFDA countries 9 CEPs with EDQM Manufacturing facility 4
Slide 12: Journey So Far
Journey So Far 2008 2010 2013 2015 2018 2021 2023 CEP granted for Pentoxifylline, Incorporation & CEP granted for COFEPRIS EUGMP and CEP granted for Esketamine Hydrochloride and The Company conversion from Chlorphenamine and KFDA EDQM approval Brompheniramine Salbutamol Sulphate; commenced a partner
Slide 13: Company Differentiators
Company Differentiators Significant scale with leadership position across key & niche products Backward integrated business model Geographically diversified revenues with a global presence across 86 countries Advanced manufacturing and research and development capabilities Experienced senior managem
Slide 14: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of Protection against Less Dependence On External Increasing margins essential raw materials market fluctuations Parties Integrated business model helped us grow revenue and
Slide 15: Diversified Geographic Presence
Diversified Geographic Presence • For key products we are seeing good traction in untapped regulated markets of North America • For Anaesthetic therapy 3 ANDA projects have been initiated and we are also working on ANDA projects for Anti Hypertensive and Vitamins Presence in 86+ Countries Across Glo
Slide 16: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a specific geography … with customer concentration Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 77.0% 76.0% 80.0% 79.0% 47% 49% 45%
Slide 17: Advanced Manufacturing and R&D Capabilities
Advanced Manufacturing and R&D Capabilities 4 7 597 KL 23,806 sq.mt. Manufacturing blocks Clean Reactor Land segregated therapy wise rooms capacity area ✓ Well delineated areas for R&D, quality control (chemical microbiology), quality assurance, dedicated areas for Scaled up Manufacturing Facilities
Slide 18: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset 18* 3* Process Patent DMFs Filed in India DSIR approved 9* 4* CEPs in 10* facility CEPs process CADIFA Brazil ✓ The Company has a DSIR approved R&D facility in Parshuram Lote, Maharashtra. ✓ Team of 26 scientists* primarily focused across the value ch
Slide 19: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets High vacuum distillations … across varied class of reactions Ability to handle complex chemistries.. Cyclisation Grignard reaction ✓ Simple to highly complex chiral centre m
Slide 20: Recognized by Key Regulatory Bodies
Recognized by Key Regulatory Bodies 19 Q1 FY25 Earnings Presentation
Slide 21: Number of API's Under Pipeline
Number of API’s Under Pipeline API’s Under Pipeline Status USDMF’s 18 API’s Submitted CEP 9 API’s Granted USDMF 2 API Submission Under Progress CEP 4 API’s Under Progress CADIFA Brazil 10 API’s Granted 20 Q1 FY25 Earnings Presentation
Slide 22: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 2017 2019 Certificate of Excellence for Special Recognition National Award Export House for the Year for Export House for the Year for Outstanding Export outstanding Export Performance in for Research and Development 2015-16 awarded by Directorate of 2016-17 awa
Slide 23: Key Management Team
Key Management Team Satish Wagh Saloni Wagh Shivani Wagh Krishna Raghunathan Executive Chairman & WTD Managing Director Joint Managing Director Chief Financial Officer • B.Sc. from R.D National College and • B.Sc. from Parle Tilak Vidhyalaya • Bachelor’s degree in management • Chartered Accountant (
Slide 24: Historical Financial Performance
Historical Financial Performance
Slide 25: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth Capex Spend … and, focus on profitability EBITDA +13.0% +15.6% 1,457 PAT 5,703.7 2,140 5,300.5 1,078 4,609.4 949 1,732 1,730 3,911.9 1,518 3,195.4 1,236 1,289 1,191 1,063 899 734 179 94 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24
Slide 26: Working Capital Break-up
Working Capital Break-up Inventory Receivables 233 73 71 206 63 61 172 165 53 130 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Payables Net Working Capital 113 235 194 196 79 75 59 124 49 105 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 No of days 25 Q1 FY25 Earnings Presentation
Slide 27: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss Particulars (in INR mn) FY24 FY23 FY22 FY21 Total Revenue 5,703.7 4,609.4 5,300.5 3,912.4 Cost of Materials Consumed 1,914.3 1,873.2 1,988.3 1,405.7 Purchase of Traded Goods - - - - Changes in Inventories of Finished Goods and Work in Progress 303.1 -65.1 -30.3 -
Slide 28: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Mar 24 Mar 23 Mar 22 Mar 21 Particulars (in INR mn) Mar 24 Mar 23 Mar 22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Equity share capital 161.0 161.0 161.0 146.4 (i) Property, plant and equipment 3,037.0 2,551
Slide 29: Summary statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars (in INR mn) FY24 FY23 FY22 FY21 Cash Flow from Operating Activities Profit before Tax 1,656.9 1,234.9 2,072.5 1,673.9 Adjustment for Non-Operating Items 24.0 72.0 68.7 53.1 Operating Profit before Working Capital Changes 1,680.9 1,306.8 2,141.2 1
Slide 30: Future Outlook
Future Outlook
Slide 31: Future Outlook
Future Outlook Two new R&D centres • The future of company lies in R&D, initiated the process of setting up enhanced R&D facility 1. The R&D lab at Lote Parshuram spread across 800 Sqm with 20 fume hoods is now commissioned and in operation. In this lab along with lifecycle management and backward i
Slide 32: Future Outlook
Future Outlook CMO/CDMO space • Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry. • Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products
Slide 33: Glossary
Glossary • API – Active Pharmaceutical Intermediates • DMF – Drug Master File • CEP – Certificate of Sustainability • USFDA – US Food And Drug Administration • EDQM – European Directorate for the Quality of Medicines & HealthCare • IDL – Import Drug Licence of China • KFDA – Korea Medical Device Reg
Slide 34: Thank You!
Thank You! Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Irfan Raeen +91 97737 78669 Mr. Krishna Raghunathan - Chief Financial Officer irfan.raeen@linkintime.co.in cfo@supriyalifescience.com Ms. Prachi Amb